|1.||Dhalla, Naranjan S: 2 articles (02/2013 - 03/2010)|
|2.||Geddes, James W: 2 articles (07/2008 - 01/2003)|
|3.||Wang, Cheng-Haung: 2 articles (01/2005 - 09/2004)|
|4.||Hung, Kuo-Sheng: 2 articles (01/2005 - 09/2004)|
|5.||Liu, Jong-Kang: 2 articles (01/2005 - 09/2004)|
|6.||Chen, Yann-Jang: 2 articles (01/2005 - 09/2004)|
|7.||Lee, Tsung-Hsing: 2 articles (01/2005 - 09/2004)|
|8.||Abbott, Jinnette D: 1 article (01/2016)|
|9.||Elmadhun, Nassrene Y: 1 article (01/2016)|
|10.||Liu, Yuhong: 1 article (01/2016)|
05/08/1998 - "Postischemic treatment with calpain inhibitor MDL 28170 ameliorates brain damage in a gerbil model of global ischemia."
01/01/2014 - "MDL28170, an inhibitor of calpain, prevented ischemia/reperfusion induced increases in LDH and infarct size, improved the LVDP recovery. "
12/02/2011 - "Inhibition of calpains using MDL-28170 decreases cardiac injury by inhibiting both cytosolic calpains and mito-μ-calpain during ischemia-reperfusion."
12/02/2011 - "Inhibition of mito-μ-calpain using MDL-28170 decreased cardiac injury by preserving AIF content within mitochondria during ischemia-reperfusion. "
05/08/1998 - "The calpain inhibitor, MDL 28170 (50 mg/kg), was initiated at 0.5 and 3 h of recirculation following 5min of global ischemia. "
11/01/1993 - "In contrast, synaptic recovery after a fixed period of hypoxia (15 minutes) was significantly improved in the Cbz-Val-Phe-H-treated slices (P < .01). "
09/19/1997 - "The calpain inhibitor, MDL28170, significantly improved the recovery of synaptic responses in hippocampal slices following prolonged, moderate hypoxia without hypoxic depolarization. "
09/19/1997 - "Neuronal recovery after moderate hypoxia is improved by the calpain inhibitor MDL28170."
12/10/1991 - "In vitro hippocampal slices from adult rats were subjected to transient hypoxia in the presence of a cell-penetrating, calpain inhibitor (Cbz-Val-Phe-H; MDL-28170). "
|3.||Neurologic Manifestations (Neurological Manifestations)
01/01/2005 - "Our study showed that intrathecal administration of MDL28170 improved neurologic dysfunction, prevented neuron loss, decreased the number of apoptotic cells, and abated astrogliosis and microglia activation 7 days after spinal cord hemisection in rats. "
01/01/2005 - "Double labeling of calpain I and phosphorylated tau (AT8) in the same cells of spinal cord lesion further implicated pathogenesis of SCI. In conclusion, MDL28170 abated calpain I activation, inhibited apoptosis and neuron loss, quenched microglia and astrocyte activation, and significantly improved neurologic deficit one week after spinal cord hemisection. "
|4.||Brain Injuries (Brain Injury)
03/10/2005 - "Macroscopic evaluation of brain injury revealed the neuroprotective effect of MDL 28170 after 12 h post-HI. "
12/01/2010 - "The cytoskeletal and neuronal protective effects of early treatment with the blood-brain barrier- and cell-permeable calpain inhibitor MDL-28170 was examined in the controlled cortical impact (CCI) traumatic brain injury (TBI) model in male CF-1 mice. "
12/01/2010 - "A pharmacological analysis of the neuroprotective efficacy of the brain- and cell-permeable calpain inhibitor MDL-28170 in the mouse controlled cortical impact traumatic brain injury model."
03/10/2005 - "MDL 28170 is a CNS-penetrating calpain inhibitor, and we examined the effects of MDL 28170 on hypoxic-ischemic brain injury in immature brain using the Rice-Vannucci model. "
03/10/2005 - "Calpain inhibitor MDL 28170 protects hypoxic-ischemic brain injury in neonatal rats by inhibition of both apoptosis and necrosis."
09/01/2012 - "Progressive RV contractile dysfunction was attenuated by MDL-28170: after 4 hours of RV pressure overload, RV systolic pressure was 44 ± 4 mm Hg versus 49 ± 6 mm Hg (P = 0.011), and RV stroke work was 72 ± 5% of baseline versus 90 ± 5% of baseline, (P = 0.027), in vehicle-treated versus MDL-28170-treated pigs, respectively. "
09/01/2012 - "MDL-28170 preserved talin abundance in the RV free wall (P = 0.039), and talin abundance correlated with the maintenance of RV free wall stroke work (r = 0.58, P = 0.0039). "
09/25/2004 - "MDL 28170, Cbz-(L)-Val-(D,L)-Phe-H, which exists as a mixture of L,L- and L,D-diastereoisomers, is a calpain inhibitor currently investigated as a novel therapeutic agent for the treatment of ischemic stroke and head and spinal trauma. "
|4.||Adenosine Triphosphatases (ATPase)
|6.||N- (4- fluorophenylsulfonyl)- L- valyl- L- leucinal
|10.||alpha- Amino- 3- hydroxy- 5- methyl- 4- isoxazolepropionic Acid (AMPA)